Being diagnosed with multiple sclerosis can, naturally, have an enormous impact on your life. You may need to make some lifestyle changes and try a few treatments to help manage the various symptoms, ...
If you are one of the 2.5 million people worldwide living with multiple sclerosis, you likely already know some of the challenges of staying active with the condition. Hearing the words “you have MS” ...
Arbaclofen extended-release (ER) reduced spasticity in patients with multiple sclerosis and was found to be safe and well-tolerated, according to 2 new abstracts presented at the 33rd Annual Meeting ...
Investigators sought to determine the safety and efficacy of twice-daily dosing of arbaclofen ER in patients with spasticity due to multiple sclerosis. SEATTLE – Twice-daily arbaclofen ...
May 24, 2012 — Spasticity is a common and disabling problem for many patients with multiple sclerosis (MS). A new study shows that smoking marijuana can relieve muscle spasms and pain in patients with ...
December 10, 2009 — Cannabis may be a viable treatment option for some patients with spasticity related to multiple sclerosis (MS), new research suggests. The systematic review, conducted by ...
Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity ...
(RTTNews) - Jazz Pharmaceuticals plc (JAZZ) said Tuesday that phase 3 RELEASE MSS1 trial, which evaluated nabiximols oromucosal spray on clinical measures of spasticity in individuals with multiple ...
DUBLIN, June 28, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 3 RELEASE MSS1 trial (NCT04657666) evaluating nabiximols oromucosal spray ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results